Original articlePancreas, biliary tract, and liverEffect of Weight Loss on Magnetic Resonance Imaging Estimation of Liver Fat and Volume in Patients With Nonalcoholic Steatohepatitis
Section snippets
Study Design and Patient Population
This is a secondary analysis of a randomized controlled trial of 43 adult patients with biopsy-proven NASH. The primary outcome was change in MRI-estimated liver PDFF and MRI-estimated liver volume between the start (week 0) and completion (week 24) of the study. All patients were diagnosed with NASH on the basis of liver biopsy as well as exclusion of other causes of liver disease.34
As part of the original study, all patients were randomized to receive either colesevelam, a bile acid
Demographic and Biochemical Data of Patients
Forty-three patients with biopsy-confirmed NASH were included in this secondary analysis of a previously published randomized controlled trail. Between the start of the study (week 0) and the completion (week 24), 10 patients had at least 5% decrease in BMI, whereas 33 patients either gained weight or had less than 5% reduction in BMI. Overall, patients who had 5% or greater decrease in BMI lost an average of 4.73 kg (± 1.87), whereas patients who either gained weight or had less than 5%
Discussion
In this secondary analysis of a randomized controlled trial that uses an advanced, validated MRI method that allows noninvasive fat quantification of the liver, we demonstrate that patients with biopsy-proven NASH with at least 5% reduction in BMI have a significant decrease in MRI-estimated liver PDFF from 18.3% ± 7.6% to 13.6% ± 13.6%, a relative decrease of 25.5%. This weight loss is also associated with a reduction in liver volume. We also found that weight loss leads to a decrease in
Strengths and Limitations
The major strengths of this study include the use of a well-characterized patient population with biopsy-proven NASH and the use of an MRI technique that has been validated as a sensitive measure of changes in liver steatosis in patients with NAFLD. This study is also unique in assessing changes in liver volume and pancreatic fat content with weight loss. In addition, histologic assessment was available at the start and completion of our study. Despite this, we do acknowledge limitations of
Conclusions
A reduction in BMI of at least 5% is associated with a significant decrease in MRI-estimated liver PDFF and volume in patients with biopsy-proven NASH. Although weight loss resulted in a decrease in histology-determined steatosis grade, no decrease in NAS or reduction in transaminases was noted. These data have implications in assessing effect size in NAFLD and obesity trials that use MRI-estimated liver fat and volume as end points.
References (41)
- et al.
Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors
Gastroenterology
(2009) - et al.
Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study
Gastroenterology
(2011) - et al.
Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial
Gastroenterology
(2008) - et al.
Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease
Gastroenterology
(2009) - et al.
Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis
Clin Gastroenterol Hepatol
(2008) - et al.
Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction
Am J Clin Nutr
(2011) - et al.
Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial
J Hepatol
(2013) - et al.
Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials
Clin Gastroenterol Hepatol
(2008) - et al.
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity
Hepatology
(2004) - et al.
The global NAFLD epidemic
Nat Rev Gastroenterol Hepatol
(2013)
Prevalence of and risk factors for hepatic steatosis in Northern Italy
Ann Intern Med
Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis
Hepatology
Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease
Aliment Pharmacol Ther
Epidemiology of non-alcoholic fatty liver disease
Dig Dis
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study
Hepatology
Fibrosis progression in nonalcoholic fatty liver versus nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies
Clin Gastroenterol Hepatol
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
N Engl J Med
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis
N Engl J Med
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials
JAMA
Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis
Aliment Pharmacol Ther
Cited by (0)
Conflicts of interest The authors disclose no conflicts.
Funding The study was conducted at the Clinical and Translational Research Institute, University of California at San Diego. R.L. is supported in part by the American Gastroenterological Association (AGA) Foundation–Sucampo–ASP Designated Research Award in Geriatric Gastroenterology and by a T. Franklin Williams Scholarship Award. Funding provided by Atlantic Philanthropies, Inc, the John A. Hartford Foundation, the Association of Specialty Professors, and the American Gastroenterological Association and grant K23-DK090303-02 and by the UCSD Digestive Diseases Research Development Center, US PHS grant #DK080506. This research was partially supported by the Clinical & Translational Research Institute (CTRI) at the University of California, San Diego. The CTRI is funded from awards issued by the National Center for Advanced Translational Sciences, UL1RR031980. Dr Seki was supported by R01DK085252, R01AA02017204, and P42ES010337. Dr Sirlin was supported by R01DK088925.